0 Commentarii
0 Distribuiri
96 Views
0 previzualizare
Căutare
Descoperă oameni noi, creează noi conexiuni și faceti-va noi prieteni
-
Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
-
GLP-1 Receptor Agonist Market Trends in Advanced Biopharmaceutical DevelopmentThe global GLP-1 Receptor Agonist Market was valued at USD 66.4 billion in 2025 and is projected to grow from USD 82.0 billion in 2026 to USD 185.3 billion by 2033, registering a CAGR of 12.4% from 2026 to 2033. The market is witnessing remarkable growth due to the rising prevalence of type 2 diabetes, obesity, and other metabolic disorders, coupled with increasing clinical acceptance...0 Commentarii 0 Distribuiri 2K Views 0 previzualizare
-
Therapeutic Radiopharmaceuticals MarketPotential: Size, Share, Trends, and Future Outlook"Future of Executive Summary GLP-1 Analogues Market: Size and Share Dynamics The global GLP-1 analogues market size was valued at USD 32.19 billion in 2024 and is expected to reach USD 346.06 billion by 2032, at a CAGR of 34.56% during the forecast period To thrive in this rapidly transforming marketplace, today’s businesses call for innovative and...0 Commentarii 0 Distribuiri 794 Views 0 previzualizare
-
Diabetes Treatments Market Size, Share, and Growth Forecast to 2030According to the latest report published by Data Bridge Market Research, the Diabetes Treatments Market Data Bridge Market Research analyses that the global diabetes treatments market which was USD 5,370.2 million in 2022, would rocket up to USD 8,920.9 million by 2030, and is expected to undergo a CAGR of 6.5 % during the forecast period. Type-1 segment dominates the type segment of...0 Commentarii 0 Distribuiri 6K Views 0 previzualizare
-
GLP-1 Market: Research Advancements and Industry DevelopmentsThe GLP-1 Market is expanding as therapeutic applications move beyond diabetes into obesity and cardiovascular disease. Valued at USD 52.82 billion in 2025, the GLP-1 Market is projected to reach USD 58.48 billion in 2026 and USD 133.92 billion by 2034, growing at a CAGR of 10.9% during the forecast period 2026–2034. Key players include AstraZeneca, Boehringer Ingelheim, D&D...0 Commentarii 0 Distribuiri 81 Views 0 previzualizare